Salehifar Ebrahim, Avan Razieh, Janbabaei Ghasem, Mousavi Seyed Khalil, Faramarzi Fatemeh
Board certified Clinical Pharmacist, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Board Certified Pharmacotherapy Specialist, Assistant Professor of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Iran J Pharm Res. 2019 Spring;18(2):1032-1039. doi: 10.22037/ijpr.2019.1100663.
Gastric cancer is the fourth common cancer and the second leading cause of cancer death worldwide. Due to lack of adequate information on the side effects of chemotherapy regimens in treatment of gastric cancer, this study was aimed to determine the side effects of two common chemotherapy regimens of gastric cancer. This prospective study was conducted in Emam Khomeini Educational Hospital and Touba Polyclinic; both are affiliated to Mazandaran University of Medical Sciences. The frequency and severity of side effects of chemotherapy were recorded based on the National Cancer Institution (NCI) Toxicity Criteria (version 2). DCF (Docetaxel, Cisplatin, 5FU) and FOLFOX (Folinic acid, 5FU, Oxaliplatin) adverse reactions were compared using SPSS 16 software. One hundred twenty five chemotherapy cycles administered to seventy four patients were assessed. The most common used regimens were DCF (70%) and FOLFOX (16%). The incidence of vomiting was higher with DCF compared to FOLFOX (P = 0.049). In more than 50% of cycles, DCF regimen caused diarrhea, while in FOLFOX regimen it was less than 9% (P = 0.002). Stomatitis, visual changes, nausea, skin reactions, and constipation were not significantly different between the two regimens. It seems that the adverse drug reactions of FOLFOX regimen were more favorable than DCF regimen. The results of this study may help clinicians choosing a more favorable chemotherapy regimen especially in patients with a low performance status who have difficulties in tolerating a chemotherapy regimen with a more severe adverse effect profile.
胃癌是全球第四大常见癌症，也是癌症死亡的第二大主要原因。由于缺乏关于化疗方案治疗胃癌副作用的充分信息，本研究旨在确定两种常见胃癌化疗方案的副作用。这项前瞻性研究在伊玛目霍梅尼教育医院和图巴综合诊所进行；这两家机构均隶属于马赞德兰医科大学。化疗副作用的频率和严重程度根据美国国立癌症研究所（NCI）毒性标准（第2版）进行记录。使用SPSS 16软件比较DCF（多西他赛、顺铂、5-氟尿嘧啶）和FOLFOX（亚叶酸、5-氟尿嘧啶、奥沙利铂）的不良反应。对74例患者进行的125个化疗周期进行了评估。最常用的方案是DCF（70%）和FOLFOX（16%）。与FOLFOX相比，DCF引起呕吐的发生率更高（P = 0.049）。在超过50%的周期中，DCF方案导致腹泻，而在FOLFOX方案中这一比例低于9%（P = 0.002）。两种方案在口腔炎、视觉变化、恶心、皮肤反应和便秘方面无显著差异。似乎FOLFOX方案的药物不良反应比DCF方案更有利。本研究结果可能有助于临床医生选择更有利的化疗方案，尤其是对于那些身体状况较差、难以耐受副作用更严重的化疗方案的患者。
